New radiation 'Smart Bomb' targets Hard-to-Treat myeloma

NCT ID NCT05363111

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tests a new treatment for multiple myeloma that has come back or stopped responding to standard therapies. The treatment combines a cancer-targeting antibody (daratumumab) with a radioactive payload to deliver radiation directly to cancer cells. The study aims to find the safest dose and check for side effects in 15 participants.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECURRENT PLASMA CELL MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma refractory plasma cell neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • City of Hope Medical Center

    RECRUITING

    Duarte, California, 91010, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact